Dr. Reckamp Discusses the Use of Hsp90 Inhibitors

Dr. Karen Reckamp from the City of Hope Cancer Center Discusses the Use of Hsp90 Inhibitors

Karen Reckamp, MD, MS, assistant professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California, discusses use of heat shock protein 90 (Hsp90) inhibition in multiple signaling pathways.

Rechamp explains that Hsp90 is being investigated not only in ALK translocated patients but also in more general uses. She describes the next step for clinical investigation is the combination of the proteins with other targeted agents such as erlotinib and gefitinib in lung cancer.